Abstract
Since the pioneering discovery of the inhibitory effects of kirromycin on bacterial elongation factor Tu (EF-Tu) more than 25 years ago [1], a great wealth of biological data has accumulated concerning protein biosynthesis inhibitors specific for EF-Tu. With the subsequent discovery of over two dozen naturally occurring EF-Tu inhibitors belonging to four different subclasses, EF-Tu has blossomed into an appealing antimicrobial target for rational drug discovery efforts. Very recently, independent crystal structure determinations of EF-Tu in complex with two potent antibiotics, aurodox and GE2270A, have provided structural explanations for the mode of action of these two compounds, and have set the foundation for the design of inhibitors with higher bioavailability, broader spectra, and greater efficacy.
Keywords: Inhibitory Mechanisms, Antibiotics Targeting Elongation Factor Tu, thermus thermophilus, the kirromycine, pulvomycin, cyclic thiazolyls, enacyloxin lla, planobispora rosea cinnamoneus, nocardialactamdurans, streptomyces, ramocissimus
Current Protein & Peptide Science
Title: Inhibitory Mechanisms of Antibiotics Targeting Elongation Factor Tu
Volume: 3 Issue: 1
Author(s): T. Hogg, J. R. Mesters and R. Hilgenfeld
Affiliation:
Keywords: Inhibitory Mechanisms, Antibiotics Targeting Elongation Factor Tu, thermus thermophilus, the kirromycine, pulvomycin, cyclic thiazolyls, enacyloxin lla, planobispora rosea cinnamoneus, nocardialactamdurans, streptomyces, ramocissimus
Abstract: Since the pioneering discovery of the inhibitory effects of kirromycin on bacterial elongation factor Tu (EF-Tu) more than 25 years ago [1], a great wealth of biological data has accumulated concerning protein biosynthesis inhibitors specific for EF-Tu. With the subsequent discovery of over two dozen naturally occurring EF-Tu inhibitors belonging to four different subclasses, EF-Tu has blossomed into an appealing antimicrobial target for rational drug discovery efforts. Very recently, independent crystal structure determinations of EF-Tu in complex with two potent antibiotics, aurodox and GE2270A, have provided structural explanations for the mode of action of these two compounds, and have set the foundation for the design of inhibitors with higher bioavailability, broader spectra, and greater efficacy.
Export Options
About this article
Cite this article as:
Hogg T., Mesters R. J. and Hilgenfeld R., Inhibitory Mechanisms of Antibiotics Targeting Elongation Factor Tu, Current Protein & Peptide Science 2002; 3 (1) . https://dx.doi.org/10.2174/1389203023380855
DOI https://dx.doi.org/10.2174/1389203023380855 |
Print ISSN 1389-2037 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5550 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Preconditioning of the Myocardium by Volatile Anesthetics
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Meloxicam Prevents Load-Induced Cardiac Hypertrophy in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Meet Our Editor:
Recent Patents on CNS Drug Discovery (Discontinued) Radical Scavenging and Antioxidant Capacity of Serotonin
Current Bioactive Compounds Biological Signatures of Alzheimer’s Disease
Current Topics in Medicinal Chemistry Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets Efficient Purification of rhG-CSF and its PEGylated Forms and Evaluation for In Vitro Activities
Protein & Peptide Letters The Effects of PDE Inhibitors on Multiple Sclerosis: a Review of <i>in vitro</i> and <i>in vivo</i> Models
Current Pharmaceutical Design Designed Multiple Ligands: Basic Research vs Clinical Outcomes
Current Medicinal Chemistry Venlafaxine and Risk of Upper Gastrointestinal Bleeding in Elderly Depression
Current Drug Safety The Synergistic Use of Computation, Chemistry and Biology to Discover Novel Peptide-Based Drugs: The Time is Right
Current Pharmaceutical Design Genetics and Molecular Biology of Tuberous Sclerosis Complex
Current Genomics Nucleic Acids as Targets for Antitelomerase Agents
Mini-Reviews in Medicinal Chemistry Enriched Environment Prevents Cognitive Impairment and Tau hyperphosphorylation after Chronic Cerebral Hypoperfusion
Current Neurovascular Research Tacrine Derivatives and Alzheimers Disease
Current Medicinal Chemistry The Heart in Sepsis: From Basic Mechanisms to Clinical Management
Current Vascular Pharmacology Regulatory Aspects of Post-Approval Safety Reporting for Generic Drug Products in the US
Applied Clinical Research, Clinical Trials and Regulatory Affairs Retromer Dysfunction and Neurodegenerative Disease
Current Genomics Depression in Sleep Related Breathing Disorder
Current Respiratory Medicine Reviews The Compound 6-Chloro-1,4-Dihydro-4-Oxo-1-(β-D-Ribofuranosyl) Quinoline-3-Carboxylic Acid Inhibits HIV-1 Replication by Targeting the Enzyme Reverse Transcriptase
Current HIV Research